Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02474407 · ClinicalTrials.gov registry record · Phase 2
Bioavailability, Safety and Tolerability of Diazepam Nasal Spray Versus Diazepam Rectal Gel (Diastat®)
A Phase 2 study, sponsored by Acorda Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 78
- Enrollment target
NCT02474407 is a Phase 2 study that was terminated before completion, run by Acorda Therapeutics. The registered enrollment target is 78 participants.
The verdict
NCT02474407, a Phase 2 study, was terminated before completion, sponsored by Acorda Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 78 participants
- Enrollment target
Study Summary
This is a multi-center, open-label, crossover, pharmacokinetic, bio-availability study involving adolescents and adults with refractory (drug-resistant) epilepsy. Cohort 1 comprises the subjects used to determine the relative bioavailability of DZNS versus DRG (Diastat)
Interventions
- DRUG diazepam nasal spray
- DRUG diazepam rectal gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2015-06 |
| Est. Completion | 2016-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02474407
The ClinicalTrials.gov registry entry for NCT02474407 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Acorda Therapeutics, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which diazepam nasal spray is the first listed.
NCT02474407 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02474407 about?
NCT02474407 is a clinical study titled "Bioavailability, Safety and Tolerability of Diazepam Nasal Spray Versus Diazepam Rectal Gel (Diastat®)". This is a multi-center, open-label, crossover, pharmacokinetic, bio-availability study involving adolescents and adults with refractory (drug-resistant) epilepsy. Cohort 1 comprises the subjects used to determine the relative bioavailability of DZNS versus DRG (Diastat)
What is the current status of trial NCT02474407?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 78 participants. The study started on 2015-06. Estimated completion is 2016-07.
What interventions are being tested in trial NCT02474407?
The interventions under investigation include: diazepam nasal spray (DRUG), diazepam rectal gel (DRUG).
Who is sponsoring clinical trial NCT02474407?
This trial is sponsored by Acorda Therapeutics, which has 36 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.